PIA
CHRS icon

Piedmont Investment Advisors’s Coherus Oncology CHRS Stock Holding History

Piedmont Investment Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-813
Closed -$11K – 1266
2018
Q2 		$11K Buy
+813
New +$11.6K ﹤0.01% 1795

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Piedmont Investment Advisors's CHRS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Coherus Oncology (CHRS) in Q3 2018, closing a stake of 813 shares — an estimated $11K sold.

Piedmont Investment Advisors first reported a position in CHRS in Q2 2018 and held it in 1 quarter. The position peaked at $11K in Q2 2018. 109 funds tracked by Wall St. Rank hold CHRS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Coherus Oncology position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 813 Coherus Oncology shares in Q3 2018, an estimated $11K.
  • Piedmont Investment Advisors first reported a position in Coherus Oncology in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Coherus Oncology position peaked at $11K in Q2 2018.
  • 109 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.